
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Video: Patient's ADLs were unaffected by symptoms until 2 days ago. She arrives at ED directly from PCP's office, after echo. Dx?

